BD's Q2 Revenues Increase 4 Percent on Diagnostics Sales Strength | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson today said that its fiscal second-quarter revenues were up almost 4 percent year over year, helped along by a 5 percent increase in the BD Diagnostics segment.

The Franklin Lakes, NJ-based company reported revenues of $2.00 billion for the three months ended March 31, compared to $1.93 billion a year ago, and just beating the consensus Wall Street estimate of $1.99 billion. On a currency-neutral basis, revenues were up a little more than 4 percent, BD said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.